



Senzime expands its commercial capability in the U.S.

Press release: Uppsala, on 20 April 2021. Senzime today announces that the company is progressing on its commercial strategy with the onboarding of additional sales representatives and the signing of a distribution agreement with Mercury Medical Enterprises, Inc.

In the US, Senzime's own salesforce has won several important deals and currently has many ongoing evaluations at large university hospitals as well as in small and medium sized hospitals. The evaluations are often the last step in the sales process before deciding on an order.

To take advantage of the opportunities the need for adequate anesthesia monitoring entails, Senzime is now expanding its commercial capacity in the US market through further recruitment of its own sales staff and by entering into distribution agreement with Mercury Medical for certain regions. This further increases the contact area with the hospitals. Mercury is a leading player in the United States in providing cutting-edge technology in the field of anesthesia - a philosophy that is fully in line with Senzime and TetraGraph.

"The sales partnership with Mercury Medical is a perfect match for both organizations as TetraGraph is an excellent complement to the current Mercury portfolio with advanced anesthesia technology. Senzime and Mercury are united in their commitment to increased patient safety", says Pia Renaudin, CEO of Senzime.

Dr. John Gargaro, President and CEO at Mercury Medical, added: "Dedicated to delivering clinically differentiated critical care technology that saves lives throughout the world, Mercury Medical believes the TetraGraph is a long overdue superior solution designed to improve outcomes for patients receiving a general anesthetic. As a company, Mercury Medical has a rich experience in introducing innovative, clinically differentiated medical devices to market. TetraGraph is just such a product. We are extremely pleased to partner with Senzime in this critical endeavor to advance safety in the surgical realm."

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Phone: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com

About Mercury Medical

For over 55 years clinicians have relied on Mercury Medical as their resource for quickly responding to clinical needs with solutions that effectively improve patient outcomes. As both a global manufacturer and distributor, the company provides a legacy of innovative products to anesthesia, respiratory, neonatal and emergency markets. Mercury Medical's high-quality standards include ISO 13485 and ISO 9001 certifications. www.mercurymed.com